05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£21,325,699 |
Nicolas Loebel |
3,538,991 |
£482,820 |
Junaid Bajwa |
1,193,697 |
£162,854 |
Jean Duvall |
1,163,529 |
£158,739 |
Jean Charest |
353,356 |
£48,208 |
Simon Sinclair |
256,327 |
£34,970 |
Carolyn Cross |
118,091,377 |
£16,111,038 |
M&G Plc |
40,588,235 |
£5,537,395 |
Robert Cross |
25,858,400 |
£3,527,824 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,060,874 |
CRUX Asset Management |
9,298,090 |
£1,268,525 |
Chelverton Asset Management |
7,957,311 |
£1,085,605 |
11:05 |
10,986 @ 14.40p |
10:46 |
12,500 @ 14.38p |
10:10 |
14 @ 13.50p |
09:46 |
676 @ 14.50p |
09:22 |
8,433 @ 14.37p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research